New depression pill gets first human safety check
NCT ID NCT07371065
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new tablet called LY03021 in 98 healthy adults aged 18 to 45. The main goal is to check safety and how the body processes the drug. It is a first step before testing the drug in people with depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 604 Lingling Road, Shanghai
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a structured care pathway ease teen depression?
- Can a nasal spray break through tough depression?
- Could a new drug offer hope for Treatment-Resistant depression?
- Targeting depression: can MRI-Guided brain zaps rewire key circuits?
- Can a psychedelic trip plus a gentle ear zap lift depression?
- Can a smart brain implant outsmart depression?